RESUMEN
The estrogen receptor (ER)-alpha protein and ER mRNA were measured in 314 primary breast cancer patients by enzyme immunoassay (EIA) and reverse-transcription polymerase chain reaction (RT-PCR) assay, respectively. The positivity of ER protein was 53% while of ER mRNA was 37.6%. A significant positive association between ER phenotype and ER mRNA was observed (r = 0.40, p < 0.0001) with a positive-negative agreement between them of 71.8%. The percentage of ER-negative, progesterone receptor (PR)-positive breast tumors was 1.9% by EIA and 7% by RT-PCR assay. This may indicate a difference in ER variants in these studied patients. The ER protein and ER mRNA status were inversely related to tumor size and p53 positivity. Also, ER protein was frequently positive in patients with a higher number of lymph node invasions, well to moderate nuclear differentiated tumor cells and negative c-erbB-2 status. The difference of the ER or ER mRNA status regarding ages, menopausal status, tumor stages and histological types was not shown. In the present study, ER mRNA did not demonstrate a closer relationship to prognostic indicators of breast cancer than ER protein. Before including the ER mRNA assessment in routine investigations of breast cancer, its relationship to prognostic factors and survival outcome should be further assessed with a higher number of patients and a longer follow-up time.
Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/genética , Receptor alfa de Estrógeno , Femenino , Humanos , Persona de Mediana Edad , Pronóstico , ARN Mensajero/análisis , Receptores de Estrógenos/genética , Receptores de Progesterona/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sensibilidad y Especificidad , Estadística como Asunto , Tailandia , Biomarcadores de Tumor/metabolismo , Salud de la Mujer , Microglobulina beta-2/metabolismoRESUMEN
We prospectively evaluated serum concentrations of beta 2-microglobulin in twenty healthy controls and fifty cases of CT scan proven and operated intracranial tumours. The later group comprised of twenty subjects of benign and thirty cases of malignant tumours respectively. Mean serum beta 2-microglobulin in healthy subjects was 1.80 +/- 0.5 mg/ litre, none had value of more than 3.0 mg/ltr. On the contrary 75% of benign and 63.3% of malignant tumour cases had statistically significant rise in the beta 2-microglobulin. Elevated serum level of beta 2-microglobulin may prove to be a reliable tumour marker.